冠状动脉造影评估国产尿激酶静脉溶栓治疗AMI疗效分析

本文对41例经静脉溶栓后的患者，于溶栓开始后90分钟行急诊冠状动脉造影检查，旨在探讨国产尿激酶（天普-洛欣）的血管再通率，并观察各项临床再通指标与冠状动脉造影的符合率。结果发现，国产尿激酶（天普洛欣）静脉溶栓冠脉开通率为75．6％。判断梗塞血管再通的无创指标中以心肌酶峰值前移最为准确，其次为心电图ST段下移，胸痛缓解及再灌注的心律失常不能作为判断再通的独立指标。

Intravenous thrombolysis using china-made urokinase with coronary angiographic evaluation in AMI patients

Thrombolytic therapy of acute myocardial infarction has been proven to reduce mortalityand improve the quality of life in survivors,but the index of reperfusion after thrombolysis is not sufficientlydefined. The aim of this study was to establish the Perfusion rate after China-made Urokinase (Techpool)intravenons infusion and find out the acurracy of different clinical perfusion indexes in 41 acute myocardialinfarction patients with coronary angiography 90 minutes after starting the thrombolytic agent. The resultshowed that the patent rate of the Urokinase given intravenously was 75. 6%. Earlier appearence of cardiacenzyme peak values was the most accurate index among all the clinical indexes followed by elevated ST segment returning to baseline more than 50% within 2 hours. Whereas,relief of chest and reperfusion arrhyth-mia could not be counted for the independent perfusion index.